论文部分内容阅读
本文探讨以SRCA作为抗癌药物敏感试验,对54例病员的实验研究和临床应用初步观察。54例中,实验可评价率为90.7％。临床上根据实验结果拟定化疗方案对病员进行治疗,16例不同类型中,晚期肿瘤病人的治疗有效率(CR+PR)为75.0％。病理组织学观察提示,药物处理后移植瘤块的大小与宿主细胞浸润无明显关系而主要可能是由于药物作用所致。作者将现一般采用的6天SRCA缩短为5天后,保留了6天法简便实用的特点,移植物中淋巴细胞的浸润明显减少,瘤细胞的保存率也有所提高。上述结果表明,此模型具有周期短、方法简便、同临床相关性较好的特点,为SRCA在指导肿瘤临床化疗中的应用价值开发提供了初步证据。
This article discusses the use of SRCA as an anti-cancer drug susceptibility test, preliminary observations of experimental studies and clinical applications of 54 patients. In 54 cases, the testable rate was 90.7%. According to the experimental results, patients were treated according to the experimental results. The treatment efficiency (CR+PR) of the 16 patients with different types of advanced and advanced tumors was 75.0%. Histopathological observations suggest that the size of the transplanted tumor mass after drug treatment is not significantly related to the infiltration of host cells and may be mainly due to the effect of the drug. The authors shortened the 6-day SRCA that was generally used to 5 days, and retained the 6-day method that was simple and practical. The infiltration of lymphocytes in the graft was significantly reduced, and the preservation rate of the tumor cells was also increased. The above results show that this model has the characteristics of short cycle, simple method and good clinical correlation, which provides preliminary evidence for the development of application value of SRCA in guiding clinical chemotherapy of tumors.